Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche Confident Spark Therapeutics Acquisition Will Complete In First Half

Executive Summary

US financial regulators have not been quick at reviewing Roche’s multi-billion dollar acquisition of gene therapy biotech Spark Therapeutics, but it is still on track for completion in the first half of 2019.



Related Content

Spotlight on Q1 Pharma M&A Merry-Go-Round
Deal Watch: Editas, BlueRock Ink Cross-Licensing Technology Collaboration
Hemophilia A Gene Therapy Race Intensifies With Updated Sangamo/Pfizer Data
Bluebird Bio's Zynteglo Flies Through Its CHMP Review
How Roche Won The Bidding Battle For Spark
Biogen By Buying Nightstar Targets Ophthalmology As Emerging Growth Area
Novartis Goes Big On Gene Therapy With $8.7bn AveXis Acquisition


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts